A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Genitourinary Cancer

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clgc.2013.11.020PMID 24685058PMCID PMC4623321
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

  2012cited by this paper
• Everolimus for Advanced Pancreatic Neuroendocrine Tumors

  2012cited by this paper
• Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.

  2012cited by this paper
• Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

  2012cited by this paper
• Everolimus for advanced pancreatic neuroendocrine tumors.

  2011cited by this paper
• Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.

  2011cited by this paper
• A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

  2011cited by this paper
• Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

  2011cited by this paper
• A Phase I Trial to Determine the Safety of Imatinib in Combination With Vatalanib in Patients With Advanced Malignancies

  2011cited by this paper
• A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.

  2011cited by this paper
• Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

  2011cited by this paper
• Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy

  2011cited by this paper
• Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

  2010cited by this paper
• Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model

  2010cited by this paper
• Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo

  2010cited by this paper
• Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.

  2010cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer

  2010cited by this paper
• mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

  2009cited by this paper
• Combination targeted therapy in advanced renal cell carcinoma

  2009cited by this paper
• Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2008cited by this paper
• Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

  2008cited by this paper
• Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

  2008cited by this paper
• Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• mTOR pathway and mTOR inhibitors as agents for cancer therapy.

  2008cited by this paper
• Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

  2008cited by this paper
• Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

  2008cited by this paper
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• Defining the role of mTOR in cancer.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Phase I study of everolimus in pediatric patients with refractory solid tumors.

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Molecular pathways in renal cell carcinoma--rationale for targeted treatment.

  2006cited by this paper
• Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

  2006cited by this paper
• A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.

  2006cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005cited by this paper
• Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.

  2005cited by this paper
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2005cited by this paper
• Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells

  2004cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• mTOR as a positive regulator of tumor cell responses to hypoxia.

  2004cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• A Novel Hypoxia-inducible Factor-independent Hypoxic Response Regulating Mammalian Target of Rapamycin and Its Targets*

  2003cited by this paper
• Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) ‐dependent signaling

  2002cited by this paper
• Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway*

  2002cited by this paper
• Loss of PTEN facilitates HIF-1-mediated gene expression.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper

• Water Mediated: An Efficient Synthesis of 2-Amino-6-[1,4-dioxo-3,4-dihydrophthalazin-2(1H)-yl]-4-(1H-indol-3-yl)-4H-pyran-3,5-dicarbonitriles

  2025cites this paper
• Anti-neoangiogenic nanodelivery systems: advances in tumor-based and ophthalmic disease research.

  2025cites this paper
• Advances in Drug Therapy for Gastrointestinal Stromal Tumour.

  2023cites this paper
• Onco-hypertension: Overview of hypertension with anti-cancer agents

  2021cites this paper
• Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer.

  2021cites this paper
• Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors

  2021cites this paper
• Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

  2021cites this paper
• A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

  2020cites this paper
• Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics

  2019cites this paper
• Human telomerase reverse transcriptase protein expression predicts tumour aggressiveness and survival in patients with clear cell renal cell carcinoma.

  2019cites this paper
• An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy

  2019cites this paper
• Potential Successes and Challenges of Targeted Cancer Therapies.

  2019cites this paper
• New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.

  2018cites this paper
• Lipid‐lowering therapy of everolimus‐related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)

  2018cites this paper
• Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.

  2017cites this paper
• Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma

  2017influential citation
• Clinical development of mTor inhibitors for renal cancer

  2017cites this paper
• Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy

  2017cites this paper
• The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature

  2017cites this paper
• In Vitro Assays for Endothelial Cell Functions Required for Angiogenesis: Proliferation, Motility, Tubular Differentiation, and Matrix Proteolysis.

  2016cites this paper
• Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis

  2016cites this paper
• Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

  2016cites this paper
• Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.

  2016cites this paper
• Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.

  2016cites this paper
• A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

  2015cites this paper
• Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer

  2015influential citation
• 2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib

  2015cites this paper